Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: integralife.com
Recent Analyst Ratings for Integra LifeSciences Holdings Corporation
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $25.00 → $20.00 | Underweight | Morgan Stanley |
| 10/7/2024 | Sell → Neutral | BTIG Research | |
| 7/30/2024 | $22.00 | Neutral → Sell | BTIG Research |
| 7/30/2024 | $30.00 → $23.00 | Neutral → Sell | Citigroup |
| 5/7/2024 | Outperform → Perform | Oppenheimer | |
| 5/7/2024 | $45.00 → $25.00 | Overweight → Equal Weight | Wells Fargo |
| 4/3/2024 | $38.00 | Sell → Neutral | Citigroup |
| 12/5/2023 | $40.00 → $49.00 | Equal Weight → Overweight | Wells Fargo |
| 11/14/2023 | $50.00 | Buy | CL King |
| 8/24/2023 | $44.00 | Equal-Weight → Underweight | Morgan Stanley |
Integra LifeSciences Holdings Corporation Press Releases
Fastest customizable press release news feed in the world
Integra LifeSciences to Present at the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance pati
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A w
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)
PRINCETON, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced the launch of its global medical education platform Integra Institute. This new digital resource is designed to elevate Integra's medical education offerings in surgical, neurologic, ENT and regenerative care by enhancing professional development through a wealth of on-demand learning resources. The Integra Institute platform is designed for healthcare providers (HCPs) in the United States and EMEA across multiple medical specialties, tailored to a variety of experience levels. The curated hub includes on-demand webinars o
Integra LifeSciences Reports Third Quarter 2024 Financial Results
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.Third quarter GAAP earnings per diluted share of $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.76 in the prior year.Shipping holds communicated during the second quarter ea
Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024
PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de
Integra LifeSciences to Present at the 22nd Annual Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at 10:45am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and re
Integra LifeSciences Holdings Corporation Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Morgan Stanley initiated coverage on Integra with a new price target
Morgan Stanley initiated coverage of Integra with a rating of Underweight and set a new price target of $20.00 from $25.00 previously
Integra upgraded by BTIG Research
BTIG Research upgraded Integra from Sell to Neutral
Integra downgraded by BTIG Research with a new price target
BTIG Research downgraded Integra from Neutral to Sell and set a new price target of $22.00
Integra downgraded by Citigroup with a new price target
Citigroup downgraded Integra from Neutral to Sell and set a new price target of $23.00 from $30.00 previously
Integra downgraded by Oppenheimer
Oppenheimer downgraded Integra from Outperform to Perform
Integra downgraded by Wells Fargo with a new price target
Wells Fargo downgraded Integra from Overweight to Equal Weight and set a new price target of $25.00 from $45.00 previously
Integra upgraded by Citigroup with a new price target
Citigroup upgraded Integra from Sell to Neutral and set a new price target of $38.00
Integra upgraded by Wells Fargo with a new price target
Wells Fargo upgraded Integra from Equal Weight to Overweight and set a new price target of $49.00 from $40.00 previously
CL King initiated coverage on Integra with a new price target
CL King initiated coverage of Integra with a rating of Buy and set a new price target of $50.00
Integra downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded Integra from Equal-Weight to Underweight and set a new price target of $44.00
Integra LifeSciences Holdings Corporation Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
Integra LifeSciences Holdings Corporation Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
EVP, Chief Legal Officer & Sec Schwartz Eric covered exercise/tax liability with 2,718 shares, decreasing direct ownership by 5% to 56,020 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & CHIEF FINANCIAL OFFICER Knight Lea Daniels covered exercise/tax liability with 1,655 shares and was granted 20,859 shares, increasing direct ownership by 46% to 61,139 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 443 shares and was granted 5,514 shares, increasing direct ownership by 14% to 40,882 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & President, CSS Mcbreen Michael J. covered exercise/tax liability with 2,033 shares and was granted 18,480 shares, increasing direct ownership by 31% to 70,344 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & CHRO Veillon-Berteloot Chantal covered exercise/tax liability with 524 shares and was granted 7,343 shares, increasing direct ownership by 28% to 31,198 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & President, TT Davis Robert T. Jr. covered exercise/tax liability with 1,379 shares and was granted 12,425 shares, increasing direct ownership by 17% to 75,561 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & PRESIDENT, INTERNATIONAL Singh Harvinder converted options into 2,356 shares, covered exercise/tax liability with 647 shares and was granted 9,508 shares, increasing direct ownership by 551% to 13,252 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 277 shares, decreasing direct ownership by 0.77% to 35,811 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP & President, CSS Mcbreen Michael J. covered exercise/tax liability with 2,285 shares, decreasing direct ownership by 4% to 53,897 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
EVP, Chief Legal Officer & Sec Schwartz Eric covered exercise/tax liability with 773 shares, decreasing direct ownership by 1% to 58,738 units (SEC Form 4)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
Integra LifeSciences Holdings Corporation SEC Filings
SEC Form 10-K filed by Integra LifeSciences Holdings Corporation
10-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Other Events
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
SEC Form S-8 filed by Integra LifeSciences Holdings Corporation
S-8 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation
10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation
10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
Integra LifeSciences Holdings Corporation Leadership Updates
Live Leadership Updates
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr
Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra for a limited period of time before returning to his prior role as non-executive chairman. "The board and I are thrilled to welcome Mojdeh as Integra's next president and CEO," sa
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer
Brings proven leadership and successful track record to Halda as the company enters the next stage of growth as clinical-stage company Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced that it has appointed Christian Schade as President and Chief Executive Officer and a member of the Board of Directors. Chris brings more than 20 years of public and private pharmaceutical and biotechnology industry experience, including building, financing and leading biotechnology companies through the clinical stages of pipeline development and formation of value-creating de
Alltrna Announces Updates to Its Board of Directors
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors
PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company's board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021. "I am pleased to welcome Jeff to our board of directors. He is a highly-accomplished executive with a track record of leading and transforming technically complex businesses," said Stuart Essig, chairman of the Integra board of directors. "His experience in streamlining global
Integra LifeSciences Holdings Corporation Investors: Please contact the Portnoy Law Firm to recover your losses; November 13, 2023 deadline
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Integra LifeSciences Holdings Corporation (NASDAQ:IART) investors that a lawsuit filed on behalf of investors that purchased Integra securities between March 11, 2019 and May 22, 2023, both dates inclusive. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claim
Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing
TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b
Integra LifeSciences Appoints Lea Daniels Knight, Executive Vice President and Chief Financial Officer
PRINCETON, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced the appointment of Lea Daniels Knight as executive vice president and chief financial officer, effective June 28, 2023. Ms. Knight has over 30 years of experience in global companies with significant operating scale and complexity, leading and developing high-performing teams, and demonstrating success in combining financial acumen and business process leadership with strategic vision to deliver strong business outcomes. Most recently, she served as the executive vice president of business finance for Booz Allen Hamilton where she was responsible for providing strate
Perimeter Medical Imaging AI Announces CEO Transition and New Member of the Board of Directors
TORONTO and DALLAS, June 5, 2023 /PRNewswire/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced that Jeremy Sobotta has resigned as Chief Executive Officer of the Company, effective June 15, 2023, for personal reasons. Perimeter has also announced that the Board of Directors has appointed Adrian Mendes as Chief Executive Officer, effective immediately. Mr. Sobotta will work closely with Mr. Mendes over the coming weeks to ensure a smooth transition of responsibi
Integra LifeSciences Holdings Corporation Financials
Live finance-specific insights
Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Reported revenues were $442.6 million, representing an increase of 11.5% on a reported basis and an increase of 3.5% on an organic basis compared to the fourth quarter 2023. GAAP earnings per diluted share were $0.25, compared to $0.25 in the fourth quarter 2023. Adjusted earnings per diluted share were $0.97, compared to $0.89 in the fourth quarter 2023. Full-Year 2024 Reported revenues were $1,610.5 million, representing an increase of 4.5% on a reported basis and
Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025
PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A w
Integra LifeSciences Reports Third Quarter 2024 Financial Results
PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Highlights Third quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased 10.3% on an organic basis excluding Boston.Third quarter GAAP earnings per diluted share of $(0.14), compared to $0.24 in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.76 in the prior year.Shipping holds communicated during the second quarter ea
Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024
PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the
Integra LifeSciences Reports Second Quarter 2024 Financial Results
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024. Second Quarter 2024 Highlights Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston.Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year.Early integration success with the Acclarent ENT a
Integra LifeSciences to Host Second Quarter 2024 Financial Results Conference Call on July 29, 2024
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2024 financial results on Monday, July 29, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the co
Integra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted share of $(0.04), compared to $0.29 in the prior year; adjusted earnings per diluted share of $0.55, compared to $0.74 in the prior yearCompleted the acquisition of the Acclarent, Inc. on April 1
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company's first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. EDT. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommende
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions. The addition of Acclarent's innovative product portfolio expands the breadth of Integra's market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel. The acquisition adds $1 billion to the total addressable market of the Company's offerings, while providing unique market opportunities for access to the attractive ENT device segment. "Acclarent's stro
Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Reported revenues were $397.0 million, representing a decrease of 0.2% on a reported basis and a decrease of 1.2% on an organic basis compared to the fourth quarter 2022. Revenue increased 3.6% on an organic basis excluding Boston. GAAP earnings per diluted share were $0.25, compared to $0.63 in the fourth quarter 2022. Adjusted earnings per diluted share were $0.89, compared to $0.94 in the fourth quarter of 2022. Full-Year 2023 Reported revenues were $1,541.6 mill
Integra LifeSciences Holdings Corporation Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation
SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
Amendment: SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation
SC 13G - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SEC Form SC 13G/A filed by Integra LifeSciences Holdings Corporation (Amendment)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)